Oncodesign, UCB In Early Development Pact

Oncodesign has entered into a research collaboration and exclusive license option with UCB leveraging Oncodesign’s Nanocyclix technology platform for next generation kinase inhibitors, and UCB’s expertise in neurology, to develop therapeutic solutions for neurodegenerative disorders. Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB with the aim of discovering potent and selective inhibitors that cross the blood brain barrier.
 
UCB has an exclusive option to license the joint program, with worldwide development and commercialization rights, based on reaching certain discovery milestones. Oncodesign will receive research funding, and upon exercise of the license option, a program access fee and additional research, development, regulatory and commercial milestone payments for the development of molecules in two or more indications, as well as royalties on sales.
 
“This collaboration with UCB further establishes Oncodesign as a major player in the drug discovery field. It strengthens our strategy of early partnering with leading international pharmaceutical companies in fields outside of oncology. This, together with our internal focus on innovative programs against cancer, constitutes a strong basis for addressing major unmet needs in patients and value creation,” said Philippe Genne, Ph.D., chairman and chief executive officer of Oncodesign.